anitocabtagene-autoleucel

BIOLOGICAL2 trials

Sponsors

Kite, A Gilead Company

Conditions

Multiple MyelomaRelapsed and Refractory Multiple Myeloma

Phase 1

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Active, not recruitingNCT04155749

Kite, A Gilead CompanyRelapsed and Refractory Multiple Myeloma

Start: 2019-12-23End: 2027-05-01Updated: 2026-02-11

Phase 2

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Active, not recruitingNCT05396885

Kite, A Gilead CompanyMultiple Myeloma

Start: 2022-07-15End: 2026-12-01Updated: 2026-02-11

Related Papers

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Blood2025-11-03

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood2024-11-0516 citations

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Blood2024-11-058 citations

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain

Molecular Cancer Therapeutics2022-06-2318 citations

Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.

Journal of Clinical Oncology2022-06-016 citations

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

Blood Advances2022-04-2567 citations

Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.

Journal of Clinical Oncology2021-05-207 citations

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Blood2020-11-058 citations